REGENXBIO

NAS:RGNX

Biotechnology

Market Cap

$1.67bn

SMALL cap

Share Price ↑

$46.50 (1.80%)

YTD Return ↑

7.3159%

since start of 2019

P/E Ratio

—

RGNX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 2008

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

website

Source: FactSet Research Systems

Headquarters

9712 Medical Center Drive

Suite 100

Rockville, MD 20850

1.240.552.8181

Executives

Name	Title	Gender
Patrick J. Christmas	Senior Vice President & General Counsel	Male
Donald J. Hayden, Jr., MBA	Chairman	Male
Kenneth T. Mills	President, Chief Executive Officer & Director	Male
Vit Vasista, MBA	CFO & Principal Accounting Officer	Male
Olivier Danos, PhD	Chief Scientific Officer	Male
Stephen Yoo, MD	Chief Medical Officer	Male
Kimberly Sloan	Senior Vice President-Human Resources	Female
Lynne Fahey McGrath, PhD	Vice President-Regulatory Affairs	Female
James M. Wilson, MD, PhD	Founder	null
Rickey Reinhardt, MD, PhD	Vice President-Clinical Research & Development	null
Jerome W. Jackson, MBA	Vice President-Information Technology	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

REGENXBIO among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

REGENXBIO on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

REGENXBIO among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

REGENXBIO among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

REGENXBIO compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

REGENXBIO among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

REGENXBIO among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

REGENXBIO among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

REGENXBIO compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

REGENXBIO among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

REGENXBIO compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 1 N/A

REGENXBIO performs very poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

REGENXBIO - Competitors and Related Companies

How REGENXBIO stacks up to its peers in the Biotechnology industry or with competing business segments.

REGENXBIO

NAS:RGNX

Biotechnology

Market Cap

$1.67bn

SMALL cap

Share Price ↑

$46.50 (1.80%)

YTD Return ↑

7.3159%

since start of 2019

P/E Ratio

—

RGNX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

Loading…